EXTRAWELL PHAR (00858) announces that it is expected to achieve a mid-term profit of approximately HK$100 million to HK$105 million, turning a loss into a profit on a year-on-year basis.
Excellent Pharmaceutical (00858) announced that the group expects to achieve profitability for the six months ending September 30, 2024.
EXTRAWELL PHAR (00858) has announced that the group is expected to achieve a profit of approximately HK$100 million to HK$105 million for the six months ending on September 30, 2024, compared to a loss for the same period ending on September 30, 2023. The expected turnaround from loss to profit for this period is mainly due to non-cash items, specifically income generated from fair value changes in financial assets recognized in the income statement, as opposed to losses from fair value changes in the same non-cash items for the corresponding period in 2023.
Related Articles
CITIC SEC (06030): Wu Yonggao appointed as non-executive director
Wall Street is also surprised! Micron Technology (MU.US) pricing is unexpectedly strong, Wedbush directly raised its target price to $500.
CITIC (00267): Citic Heavy Industries (601608.SH) is expected to have a net profit attributable to the parent of around 375 million yuan in 2025, a year-on-year increase of 0.24%.
CITIC SEC (06030): Wu Yonggao appointed as non-executive director
Wall Street is also surprised! Micron Technology (MU.US) pricing is unexpectedly strong, Wedbush directly raised its target price to $500.
CITIC (00267): Citic Heavy Industries (601608.SH) is expected to have a net profit attributable to the parent of around 375 million yuan in 2025, a year-on-year increase of 0.24%.
RECOMMEND
“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026
Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026
U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026
